Page 173 - NobleCon19revC2_Neat

Unicycive Therapeutics, Inc.

SELECTED FINANCIAL ITEMS UNCY

(in millions of USD)
CQ4 '22 CQ1 '23 CQ2 '23 CQ3 '23 LTM
Income Statement Key Items
Total Revenue 0.00 0.68 NA NA 0.68
Gross Profit 0.00 0.68 NA NA 0.68
Gross Margin NM 100% NM NM 100%
EBIT (5.33) (4.20) (4.32) (5.94) (19.79)
EBIT Margin NM -623% NM NM -2931%
Net Income to Common Shareholders (5.33) (14.58) (3.84) (4.33) (28.07)
Net Margin NM -2159% NM NM -4159%

Balance Sheet Key Items
Total Assets 2.82 27.20 22.88 19.44 19.44
Cash & Short Term Investments 0.46 24.33 18.82 14.35 14.35
% of Assets 16% 89% 82% 74% 74%
Current Assets -Total 2.64 26.18 21.93 18.57 18.57
% of Assets 94% 96% 96% 96% 96%
Total Liabilities 3.28 16.69 16.05 16.01 16.01
% of Assets 117% 61% 70% 82% 82%
Current Liabilities - Total 3.28 15.97 15.42 15.46 15.46
% of Assets 117% 59% 67% 79% 79%
Long Term Debt NA NA NA NA NA
% of Assets NM NM NM NM NM
Total Equity (0.47) 10.52 6.83 3.43 3.43
% of Assets -17% 39% 30% 18% 18%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (6.08) (3.92) (5.50) (4.42) (19.93)
Net Cash Flow - Investing 0.00 NA (0.01) 0.00 (0.01)
Net Cash Flow - Financing (0.47) 27.80 0.00 (0.05) 27.28

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Nineteenth Annual Small & Microcap Investor Conference